Uterine fibroid embolization device market seen topping $7.33 billion by 2030

The global uterine fibroid embolization device market is projected to grow from $5.93 billion in 2025 to $6.19 billion in 2026, with North America leading the market. The Business Research Company says demand is rising as minimally invasive, uterus-preserving fibroid treatments gain favor across hospitals, clinics and outpatient settings.

Why it matters: - Uterine fibroid embolization devices are gaining traction as more women and clinicians favor minimally invasive, organ-preserving treatment for fibroids. - The market’s projected growth signals more use of interventional radiology tools, advanced catheters and embolic systems in gynecological care. - Broader adoption could expand access to treatment options that reduce recovery time and avoid major surgery.

What happened: - The Business Research Company released a 2026 market report on the uterine fibroid embolization device market. - The market is projected to rise from $5.93 billion in 2025 to $6.19 billion in 2026, a 4.4% CAGR. - The market is forecast to reach $7.33 billion by 2030 at a 4.3% CAGR. - North America held the largest regional share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

The details: - Uterine fibroid embolization devices treat benign uterine fibroids through a minimally invasive procedure that blocks blood supply to the growths. - The devices are designed to shrink fibroids over time and help patients avoid major surgery. - Market growth is being driven by a rising incidence of uterine fibroids among women of reproductive age. - Hospitals and clinics are performing more gynecological procedures that use uterine artery embolization techniques. - Demand is rising for uterus-preserving fibroid treatments, especially among younger women. - The report points to broader use in ambulatory surgical centers and outpatient settings. - Investment is increasing in delivery catheters and embolic systems intended to improve treatment accuracy. - The report highlights growing use of image-guided interventional devices for targeted fibroid therapy.

Between the lines: - The market’s steady growth suggests fibroid care is shifting away from open surgery and toward targeted, procedure-based treatment. - Interest in minimally invasive care is not limited to fibroid treatment; a US-based medical journal, AOS Open, reported in January 2025 that minimally invasive surgeries in hospitals equipped with robotic-assisted systems rose to 65.8% in 2025 from 60.5% in 2022. - North America’s lead reflects established healthcare infrastructure, higher awareness and wider adoption of minimally invasive treatment methods. - The report’s new features, including TAM analysis, scoring matrices and dashboards, are aimed at helping companies identify market hotspots and technology trends.

What's next: - The market is expected to keep expanding as more providers adopt embolization procedures in outpatient and ambulatory settings. - Future demand is likely to center on precision delivery systems that improve procedural safety and patient outcomes. - The Business Research Company expects continued interest in organ-preserving alternatives to hysterectomies and in image-guided treatment tools.

The bottom line: - Uterine fibroid embolization is moving from a niche procedure toward a more mainstream, minimally invasive option in fibroid care, with steady market growth expected through 2030.